| Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo … L Ji, L Gao, H Jiang, J Yang, L Yu, J Wen, C Cai, H Deng, L Feng, B Song, ... EClinicalMedicine 54, 2022 | 33 | 2022 |
| C/EBPα deficiency in podocytes aggravates podocyte senescence and kidney injury in aging mice L Zhang, F Zhou, X Yu, Y Zhu, Y Zhou, J Liu, Y Liu, Q Ma, Y Zhang, ... Cell death & disease 10 (10), 684, 2019 | 32 | 2019 |
| IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending … L Ji, H Jiang, P An, H Deng, M Liu, L Li, L Feng, B Song, H Han-Zhang, ... EClinicalMedicine 39, 2021 | 30 | 2021 |
| PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+ T cells and promoting fatty acid metabolism P Sun, X Zhang, RJ Wang, QY Ma, L Xu, Y Wang, HP Liao, HL Wang, ... Journal for ImmunoTherapy of Cancer 9 (8), 2021 | 28 | 2021 |
| ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression Q Ma, K Wu, H Li, H Li, Y Zhu, G Hu, L Hu, X Kong Scientific reports 9 (1), 20021, 2019 | 26 | 2019 |
| A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes H Jiang, S Pang, Y Zhang, T Yu, M Liu, H Deng, L Li, L Feng, B Song, ... Nature Communications 13 (1), 3613, 2022 | 25 | 2022 |
| Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer X Liu, Y Xu, Y Wang, Y Chen, B Wang, Y Wang, Y Chen, C Tan, L Hu, ... Cancer Letters 433, 273-282, 2018 | 15 | 2018 |
| Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2) M Chai, Y He, W Zhao, X Han, G Zhao, X Ma, P Qiao, D Shi, Y Liu, W Han, ... BMC medicine 21 (1), 77, 2023 | 11 | 2023 |
| Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells Y Wang, X Zhang, Q Ma, L Hu, X Zhang, Y Wang, L Xu, C Yang, C Tan, ... Cell Death & Disease 12 (1), 85, 2021 | 10 | 2021 |
| Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 2 trial B Zhang, Z Cheng, J Chen, X Zhang, D Liu, H Jiang, G Ma, X Wang, ... Diabetes Care 47 (1), 160-168, 2024 | 6 | 2024 |
| A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity L Ji, H Jiang, Z Cheng, W Qiu, L Liao, Y Zhang, X Li, S Pang, L Zhang, ... Nature Communications 14 (1), 8289, 2023 | 6 | 2023 |
| Genome‐wide gain‐of‐function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma H Xing, M Gao, Y Wang, X Zhang, J Shi, X Wang, X Liu, Q Ma, X Kong, ... Clinical and Translational Medicine 12 (5), e835, 2022 | 6 | 2022 |
| Progress and challenges of personalized neoantigens in the clinical treatment of tumors H Zhang, X Zhou, D Liu, Y Zhu, Q Ma, Y Zhang Medicine in Drug Discovery 6, 100030, 2020 | 6 | 2020 |
| Revisiting Non-BRCA1/2 Familial Whole Exome Sequencing Datasets Implicates NCK1 as a Cancer Gene J Yin, K Wu, Q Ma, H Dong, Y Zhu, L Hu, X Kong Frontiers in Genetics 10, 527, 2019 | 6 | 2019 |
| Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial Y Huo, Y Li, P Zhang, H Deng, H Li, P An, F Xue, Z Yu, Q Ma, L Qi, B Chen, ... Circulation 146 (Suppl_1), A10111-A10111, 2022 | 3 | 2022 |
| Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors X Zhang, Y Wang, X Zhang, Y Shen, K Yang, Q Ma, Y Qiao, J Shi, Y Wang, ... Signal Transduction and Targeted Therapy 8 (1), 153, 2023 | 2 | 2023 |
| Natural Selection on Exonic SNPs Shapes Allelic Expression Imbalance (AEI) Adaptability in Lung Cancer Progression J Huang, Y Zhang, Q Ma, Y Zhang, M Wang, Y Zhou, Z Xing, M Jin, L Hu, ... Frontiers in Genetics 11, 665, 2020 | 1 | 2020 |
| Pharmacokinetic/LDL‐C and exposure–response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies S Yan, X Zhao, Q Xie, W Du, Q Ma, T Zhu, H Deng, L Qian, S Zheng, Y Cui Clinical and Translational Science 16 (12), 2791-2803, 2023 | | 2023 |
| Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study J He, W Du, H Yang, J Wang, C Cai, Q Ma, N Li, J Yu, X Wu, J Wu, Y Chen, ... Expert Opinion on Investigational Drugs 32 (7), 669-675, 2023 | | 2023 |
| Intact regulation of G1/S transition renders esophageal squamous cell carcinomas sensitive to PI3Kα inhibitors by blocking SKP2-mediated p21 degradation Y Wang, X Zhang, X Zhang, Y Shen, Q Ma, Y Qiao, Y Wang, B Yang, L Xu, ... Cancer Research 82 (12_Supplement), 5373-5373, 2022 | | 2022 |
Guohong HuInstitute of Nutrition and Health, Chinese Academy of SciencesVerified email at sibs.ac.cn
